KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Work In Process (2016 - 2025)

CareDx (CDNA) has disclosed Work In Process for 10 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Work In Process fell 1.4% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 1.4% year-over-year, with the annual reading at $3.7 million for FY2025, 1.4% down from the prior year.
  • Work In Process hit $3.7 million in Q4 2025 for CareDx, down from $5.1 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $5.6 million in Q2 2025 to a low of $2.8 million in Q3 2021.
  • Historically, Work In Process has averaged $4.2 million across 5 years, with a median of $4.1 million in 2024.
  • Biggest five-year swings in Work In Process: surged 90.5% in 2021 and later dropped 26.94% in 2024.
  • Year by year, Work In Process stood at $2.8 million in 2021, then surged by 52.26% to $4.3 million in 2022, then increased by 20.55% to $5.2 million in 2023, then decreased by 26.93% to $3.8 million in 2024, then decreased by 1.4% to $3.7 million in 2025.
  • Business Quant data shows Work In Process for CDNA at $3.7 million in Q4 2025, $5.1 million in Q3 2025, and $5.6 million in Q2 2025.